<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34841515</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5381</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>179</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of pharmacology</Title>
          <ISOAbbreviation>Br J Pharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Proteinase-activated receptor-2 antagonist C391 inhibits Alternaria-induced airway epithelial signalling and asthma indicators in acute exposure mouse models.</ArticleTitle>
        <Pagination>
          <StartPage>2208</StartPage>
          <EndPage>2222</EndPage>
          <MedlinePgn>2208-2222</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15745</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND PURPOSE" NlmCategory="OBJECTIVE">Despite the availability of a variety of treatment options, many asthma patients have poorly controlled disease with frequent exacerbations. Proteinase-activated receptor-2 (PAR2) has been identified in preclinical animal models as important to asthma initiation and progression following allergen exposure. Proteinase activation of PAR2 raises intracellular Ca<sup>2+</sup> , inducing MAPK and β-arrestin signalling in the airway, leading to inflammatory and protective effects. We have developed C391, a potent PAR2 antagonist effective in blocking peptidomimetic- and trypsin-induced PAR2 signalling in vitro as well as reducing inflammatory PAR2-associated pain in vivo. We hypothesized that PAR2 antagonism by C391 would attenuate allergen-induced acutely expressed asthma indicators in murine models.</AbstractText>
          <AbstractText Label="EXPERIMENTAL APPROACH" NlmCategory="METHODS">We evaluated the ability of C391 to alter Alternaria alternata-induced PAR2 signalling pathways in vitro using a human airway epithelial cell line that naturally expresses PAR2 (16HBE14o-) and a transfected embryonic cell line (HEK 293). We next evaluated the ability for C391 to reduce A. alternata-induced acutely expressed asthma indicators in vivo in two murine strains.</AbstractText>
          <AbstractText Label="KEY RESULTS" NlmCategory="RESULTS">C391 blocked A. alternata-induced, PAR2-dependent Ca<sup>2+</sup> and MAPK signalling in 16HBE14o- cells, as well as β-arrestin recruitment in HEK 293 cells. C391 effectively attenuated A. alternata-induced inflammation, mucus production, mucus cell hyperplasia and airway hyperresponsiveness in acute allergen-challenged murine models.</AbstractText>
          <AbstractText Label="CONCLUSIONS AND IMPLICATIONS" NlmCategory="CONCLUSIONS">To our best knowledge, this is the first demonstration of pharmacological intervention of PAR2 to reduce allergen-induced asthma indicators in vivo. These data support further development of PAR2 antagonists as potential first-in-class allergic asthma drugs.</AbstractText>
          <CopyrightInformation>© 2021 The British Pharmacological Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rivas</LastName>
            <ForeName>Candy M</ForeName>
            <Initials>CM</Initials>
            <AffiliationInfo>
              <Affiliation>Physiological Sciences Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yee</LastName>
            <ForeName>Michael C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Sciences, University of California Riverside, Riverside, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Addison</LastName>
            <ForeName>Kenneth J</ForeName>
            <Initials>KJ</Initials>
            <AffiliationInfo>
              <Affiliation>Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Molecular Medicine, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lovett</LastName>
            <ForeName>Marissa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Physiological Sciences Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pal</LastName>
            <ForeName>Kasturi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Sciences, University of California Riverside, Riverside, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ledford</LastName>
            <ForeName>Julie G</ForeName>
            <Initials>JG</Initials>
            <AffiliationInfo>
              <Affiliation>Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Molecular Medicine, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dussor</LastName>
            <ForeName>Gregory</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Price</LastName>
            <ForeName>Theodore J</ForeName>
            <Initials>TJ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vagner</LastName>
            <ForeName>Josef</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Bio5 Collaborative Research Institute, University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>DeFea</LastName>
            <ForeName>Kathryn A</ForeName>
            <Initials>KA</Initials>
            <AffiliationInfo>
              <Affiliation>Biomedical Sciences, University of California Riverside, Riverside, California, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Corporate Headquarters, PARMedics, Inc., Temecula, California, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boitano</LastName>
            <ForeName>Scott</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Physiological Sciences Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cellular and Molecular Medicine, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Bio5 Collaborative Research Institute, University of Arizona, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, University of Arizona Health Sciences, Tucson, Arizona, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>HL160424</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>NS098826</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Pharmacol</MedlineTA>
        <NlmUniqueID>7502536</NlmUniqueID>
        <ISSNLinking>0007-1188</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000485">Allergens</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D044464">Receptor, PAR-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000485" MajorTopicYN="N">Allergens</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000528" MajorTopicYN="N">Alternaria</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044464" MajorTopicYN="Y">Receptor, PAR-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Alternaria alternata</Keyword>
        <Keyword MajorTopicYN="N">C391</Keyword>
        <Keyword MajorTopicYN="N">PAR2</Keyword>
        <Keyword MajorTopicYN="N">airway hyperresponsiveness</Keyword>
        <Keyword MajorTopicYN="N">airway inflammation</Keyword>
        <Keyword MajorTopicYN="N">allergen-induced asthma</Keyword>
        <Keyword MajorTopicYN="N">mucus cell hyperplasia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34841515</ArticleId>
        <ArticleId IdType="doi">10.1111/bph.15745</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Adam, E., Hansen, K. K., Astudillo Fernandez, O., Coulon, L., Bex, F., Duhant, X., Jaumotte, E., Hollenberg, M. D., &amp; Jacquet, A. (2006). The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. The Journal of Biological Chemistry, 281, 6910-6923. https://doi.org/10.1074/jbc.M507140200</Citation>
        </Reference>
        <Reference>
          <Citation>Addison, K. J., Morse, J., Robichaud, A., Daines, M. O., &amp; Ledford, J. G. (2017). A novel in vivo system to test bronchodilators. Journal of Infectious Pulmonary Disease, 3, 2470-3126. https://doi.org/10.16966/2470-3176.12</Citation>
        </Reference>
        <Reference>
          <Citation>Aikawa, T., Shimura, S., Sasaki, H., Ebina, M., &amp; Takishima, T. (1992). Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest, 101, 916-921. https://doi.org/10.1378/chest.101.4.916</Citation>
        </Reference>
        <Reference>
          <Citation>Alexander, S. P., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Koesling, D., … Wong S. S. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 178, S313-S411. https://doi.org/10.1111/bph.15542</Citation>
        </Reference>
        <Reference>
          <Citation>Andersson, C., Tufvesson, E., Diamant, Z., &amp; Bjermer, L. (2016). Revisiting the role of the mast cell in asthma. Current Opinion in Pulmonary Medicine, 22, 10-17. https://doi.org/10.1097/MCP.0000000000000228</Citation>
        </Reference>
        <Reference>
          <Citation>Arizmendi, N. G., Abel, M., Mihara, K., Davidson, C., Polley, D., Nadeem, A., el Mays, T., Gilmore, B. F., Walker, B., Gordon, J. R., Hollenberg, M. D., &amp; Vliagoftis, H. (2011). Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. Journal of Immunology, 186, 3164-3172. https://doi.org/10.4049/jimmunol.0903812</Citation>
        </Reference>
        <Reference>
          <Citation>Asaduzzaman, M., Nadeem, A., Arizmendi, N., Davidson, C., Nichols, H. L., Abel, M., Ionescu, L. I., Puttagunta, L., Thebaud, B., Gordon, J., DeFea, K., Hollenberg, M. D., &amp; Vliagoftis, H. (2015). Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. Clinical and Experimental Allergy, 45, 1844-1855. https://doi.org/10.1111/cea.12628</Citation>
        </Reference>
        <Reference>
          <Citation>Avet, C., Sturino, C., Grastilleur, S., Gouill, C. L., Semache, M., Gross, F., Gendron, L., Bennani, Y., Mancini, J. A., Sayegh, C. E., &amp; Bouvier, M. (2020). The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects. Communications Biology, 3, 719-731. https://doi.org/10.1038/s42003-020-01453-8</Citation>
        </Reference>
        <Reference>
          <Citation>Batra, M., Vicendese, D., Newbigin, E., Lambert, K. A., Tang, M., Abramson, M. J., Dharmage, S. C., &amp; Erbas, B. (2021). The association between outdoor allergens-pollen, fungal spore season and high asthma admission days in children and adolescents. International Journal of Environmental Health Research, 1-10. https://doi.org/10.1080/09603123.2021.1885633</Citation>
        </Reference>
        <Reference>
          <Citation>Boitano, S., Flynn, A. N., Sherwood, C. L., Schulz, S. M., Hoffman, J., Gruzinova, I., &amp; Daines, M. O. (2011). Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2. American Journal of Physiology. Lung Cellular and Molecular Physiology, 300, L605-L614. https://doi.org/10.1152/ajplung.00359.2010</Citation>
        </Reference>
        <Reference>
          <Citation>Boitano, S., Hoffman, J., Flynn, A. N., Asiedu, M. N., Tillu, D. V., Zhang, Z., Sherwood, C. L., Rivas, C. M., DeFea, K. A., Vagner, J., &amp; Price, T. J. (2015). The novel PAR2 ligand C391 blocks multiple PAR2 signaling pathways in vitro and in vivo. British Journal of Pharmacology, 172, 4535-4545. https://doi.org/10.1111/bph.13238</Citation>
        </Reference>
        <Reference>
          <Citation>Bush, R. K., &amp; Prochnau, J. J. (2004). Alternaria-induced asthma. The Journal of Allergy and Clinical Immunology, 113, 227-234. https://doi.org/10.1016/j.jaci.2003.11.023</Citation>
        </Reference>
        <Reference>
          <Citation>Cheng, R. K. Y., Fiez-Vandal, C., Schlenker, O., Edman, K., Aggeler, B., Brown, D. G., Brown, G. A., Cooke, R. M., Dumelin, C. E., Doré, A. S., Geschwindner, S., Grebner, C., Hermansson, N. O., Jazayeri, A., Johansson, P., Leong, L., Prihandoko, R., Rappas, M., Soutter, H., … Dekker, N. (2017). Structural insight into allosteric modulation of protease-activated receptor 2. Nature, 545, 112-115. https://doi.org/10.1038/nature22309</Citation>
        </Reference>
        <Reference>
          <Citation>Chiu, L. L., Perng, D. W., Yu, C. H., Su, S. N., &amp; Chow, L. P. (2007). Mold allergen, pen C 13, induces IL-8 expression in human airway epithelial cells by activating protease-activated receptor 1 and 2. Journal of Immunology, 178, 5237-5244. https://doi.org/10.4049/jimmunol.178.8.5237</Citation>
        </Reference>
        <Reference>
          <Citation>Cocks, T. M., Fong, B., Chow, J. M., Anderson, G. P., Frauman, A. G., Goldie, R. G., Henry, P. J., Carr, M. J., Hamilton, J. R., &amp; Moffatt, J. D. (1999). A protective role for protease-activated receptors in the airways. Nature, 398, 156-160. https://doi.org/10.1038/18223</Citation>
        </Reference>
        <Reference>
          <Citation>Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., Stanford, S. C., Teixeira, M. M., Wonnacott, S., &amp; Ahluwalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers. British Journal of Pharmacology, 175, 987-993. https://doi.org/10.1111/bph.14153</Citation>
        </Reference>
        <Reference>
          <Citation>Davidson, C. E., Asaduzzaman, M., Arizmendi, N. G., Polley, D., Wu, Y., Gordon, J. R., Hollenberg, M. D., Cameron, L., &amp; Vliagoftis, H. (2013). Proteinase-activated receptor-2 activation participates in allergic sensitization to house dust mite allergens in a murine model. Clinical and Experimental Allergy, 43, 1274-1285. https://doi.org/10.1111/cea.12185</Citation>
        </Reference>
        <Reference>
          <Citation>Ebeling, C., Forsythe, P., Ng, J., Gordon, J. R., Hollenberg, M., &amp; Vliagoftis, H. (2005). Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. The Journal of Allergy and Clinical Immunology, 115, 623-630. https://doi.org/10.1016/j.jaci.2004.11.042</Citation>
        </Reference>
        <Reference>
          <Citation>Flynn, A. N., Tillu, D. V., Asiedu, M. N., Hoffman, J., Vagner, J., Price, T. J., &amp; Boitano, S. (2011). The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo. The Journal of Biological Chemistry, 286, 19076-19088. https://doi.org/10.1074/jbc.M110.185264</Citation>
        </Reference>
        <Reference>
          <Citation>Forbes, B., Shah, A., Martin, G. P., &amp; Lansley, A. B. (2003). The human bronchial epithelial cell line 16HBE14o− as a model system of the airways for studying drug transport. International Journal of Pharmaceutics, 257, 161-167. https://doi.org/10.1016/S0378-5173(03)00129-7</Citation>
        </Reference>
        <Reference>
          <Citation>Goh, F. G., Ng, P. Y., Nilsson, M., Kanke, T., &amp; Plevin, R. (2009). Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. British Journal of Pharmacology, 158, 1695-1704. https://doi.org/10.1111/j.1476-5381.2009.00415.x</Citation>
        </Reference>
        <Reference>
          <Citation>Gruenert, D. C., Finkbeiner, W. E., &amp; Widdicombe, J. H. (1995). Culture and transformation of human airway epithelial cells. The American Journal of Physiology, 268, L347-L360. https://doi.org/10.1152/ajplung.1995.268.3.L347</Citation>
        </Reference>
        <Reference>
          <Citation>Grynkiewicz, G., Poenie, M., &amp; Tsien, R. Y. (1985). A new generation of Ca2+ indicators with greatly improved fluorescence properties. The Journal of Biological Chemistry, 260, 3440-3450. https://doi.org/10.1016/S0021-9258(19)83641-4</Citation>
        </Reference>
        <Reference>
          <Citation>Hassler, S. N., Ahmad, F. B., Burgos-Vega, C. C., Boitano, S., Vagner, J., Price, T. J., &amp; Dussor, G. (2019). Protease activated receptor 2 (PAR2) activation causes migraine-like pain behaviors in mice. Cephalalgia, 39, 111-122. https://doi.org/10.1177/0333102418779548</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman, J., Flynn, A., Tillu, D., Zhang, Z., Patek, R., Price, T., Vagner, J., &amp; Boitano, S. (2012). Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis. Bioconjugate Chemistry, 23, 2098-2104. https://doi.org/10.1021/bc300300q</Citation>
        </Reference>
        <Reference>
          <Citation>Hollenberg, M. D., Mihara, K., Polley, D., Suen, J. Y., Han, A., Fairlie, D. P., &amp; Ramachandran, R. (2014). Biased signalling and proteinase-activated receptors (PARs): Targeting inflammatory disease. British Journal of Pharmacology, 171, 1180-1194. https://doi.org/10.1111/bph.12544</Citation>
        </Reference>
        <Reference>
          <Citation>Huang, X., Ni, B., Xi, Y., Chu, X., Zhang, R., &amp; You, H. (2019). Protease-activated receptor 2 (PAR-2) antagonist AZ3451 as a novel therapeutic agent for osteoarthritis. Aging (Albany NY), 11, 12532-12545. https://doi.org/10.18632/aging.102586</Citation>
        </Reference>
        <Reference>
          <Citation>Izzo, A. A., Teixeira, M., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Ji, Y., Kendall, D. A., Panettieri, R. A., Sobey, C. G., Stanford, S. C., Stefanska, B., Stephens, G., &amp; Ahluwalia, A. (2020). A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: Reproducibility of natural product research. British Journal of Pharmacology, 177(10), 2169-2178. https://doi.org/10.1111/bph.15054</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang, Y., Yau, M. K., Lim, J., Wu, K. C., Xu, W., Suen, J. Y., &amp; Fairlie, D. P. (2018). A potent antagonist of protease-activated receptor 2 that inhibits multiple signaling functions in human cancer cells. The Journal of Pharmacology and Experimental Therapeutics, 364, 246-257. https://doi.org/10.1124/jpet.117.245027</Citation>
        </Reference>
        <Reference>
          <Citation>Jimenez-Vargas, N. N., Pattison, L. A., Zhao, P., Lieu, T., Latorre, R., Jensen, D. D., Castro, J., Aurelio, L., le, G. T., Flynn, B., Herenbrink, C. K., Yeatman, H. R., Edgington-Mitchell, L., Porter, C. J. H., Halls, M. L., Canals, M., Veldhuis, N. A., Poole, D. P., McLean, P., … Bunnett, N. W. (2018). Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proceedings of the National Academy of Sciences of the United States of America, 115, E7438-E7447. https://doi.org/10.1073/pnas.1721891115</Citation>
        </Reference>
        <Reference>
          <Citation>Kanke, T., Ishiwata, H., Kabeya, M., Saka, M., Doi, T., Hattori, Y., Kawabata, A., &amp; Plevin, R. (2005). Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. British Journal of Pharmacology, 145, 255-263. https://doi.org/10.1038/sj.bjp.0706189</Citation>
        </Reference>
        <Reference>
          <Citation>Kanke, T., Kabeya, M., Kubo, S., Kondo, S., Yasuoka, K., Tagashira, J., Ishiwata, H., Saka, M., Furuyama, T., Nishiyama, T., Doi, T., Hattori, Y., Kawabata, A., Cunningham, M. R., &amp; Plevin, R. (2009). Novel antagonists for proteinase-activated receptor 2: Inhibition of cellular and vascular responses in vitro and in vivo. British Journal of Pharmacology, 158, 361-371. https://doi.org/10.1111/j.1476-5381.2009.00342.x</Citation>
        </Reference>
        <Reference>
          <Citation>Kennedy, A. J., Sundström, L., Geschwindner, S., Poon, E. K. Y., Jiang, Y., Chen, R., Cooke, R., Johnstone, S., Madin, A., Lim, J., Liu, Q., Lohman, R. J., Nordqvist, A., Fridén-Saxin, M., Yang, W., Brown, D. G., Fairlie, D. P., &amp; Dekker, N. (2020). Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Communications Biology, 3, 782-794. https://doi.org/10.1038/s42003-020-01504-0</Citation>
        </Reference>
        <Reference>
          <Citation>Kennedy, J. L., Heymann, P. W., &amp; Platts-Mills, T. A. (2012). The role of allergy in severe asthma. Clinical and Experimental Allergy, 42, 659-669. https://doi.org/10.1111/j.1365-2222.2011.03944.x</Citation>
        </Reference>
        <Reference>
          <Citation>Knight, D. A., Lim, S., Scaffidi, A. K., Roche, N., Chung, K. F., Stewart, G. A., &amp; Thompson, P. J. (2001). Protease-activated receptors in human airways: Upregulation of PAR-2 in respiratory epithelium from patients with asthma. The Journal of Allergy and Clinical Immunology, 108, 797-803. https://doi.org/10.1067/mai.2001.119025</Citation>
        </Reference>
        <Reference>
          <Citation>Kopruszinski, C. M., Thornton, P., Arnold, J., Newton, P., Lowne, D., Navratilova, E., Swiokla, J., Dodick, D. W., Dobson, C., Gurrell, I., Chessell, I. P., &amp; Porreca, F. (2020). Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. Cephalalgia, 40(14), 1535-1550. https://doi.org/10.1177/333102420966581</Citation>
        </Reference>
        <Reference>
          <Citation>Kouzaki, H., O'Grady, S. M., Lawrence, C. B., &amp; Kita, H. (2009). Proteases induce production of thymic stromal lymphopoietin by airway epithelial cells through protease-activated receptor-2. Journal of Immunology, 183, 1427-1434. https://doi.org/10.4049/jimmunol.0900904</Citation>
        </Reference>
        <Reference>
          <Citation>Kunzelmann, K., Sun, J., Markovich, D., König, J., Mürle, B., Mall, M., &amp; Schreiber, R. (2005). Control of ion transport in mammalian airways by protease activated receptors type 2 (PAR-2). The FASEB Journal, 19, 969-970. https://doi.org/10.1096/fj.04-2469fje</Citation>
        </Reference>
        <Reference>
          <Citation>Ledford, J. G., Addison, K. J., Francisco, D., Foster, M. W., Voelker, D. R., Que, L. G., &amp; Kraft, M. (2016). Genetic variation in surfactant protein-A2 results in altered regulation of eosinophil activities and enhanced eosinophilia in patients with asthma. Annals of the American Thoracic Society, 13(Suppl 1), S101. https://doi.org/10.1513/AnnalsATS.201508-520MG</Citation>
        </Reference>
        <Reference>
          <Citation>Lee, H. J., Yang, Y. M., Kim, K., Shin, D. M., Yoon, J. H., Cho, H. J., &amp; Choi, J. Y. (2012). Protease-activated receptor 2 mediates mucus secretion in the airway submucosal gland. PLoS ONE, 7, e43188. https://doi.org/10.1371/journal.pone.0043188</Citation>
        </Reference>
        <Reference>
          <Citation>Lieu, T., Savage, E., Zhao, P., Edgington-Mitchell, L., Barlow, N., Bron, R., Poole, D. P., McLean, P., Lohman, R. J., Fairlie, D. P., &amp; Bunnett, N. W. (2016). Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2. British Journal of Pharmacology, 173, 2752-2765. https://doi.org/10.1111/bph.13554</Citation>
        </Reference>
        <Reference>
          <Citation>Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., &amp; Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611-3616. https://doi.org/10.1111/bph.15178</Citation>
        </Reference>
        <Reference>
          <Citation>Lombardi, C., Savi, E., Ridolo, E., Passalacqua, G., &amp; Canonica, G. W. (2017). Is allergic sensitization relevant in severe asthma? Which allergens may be culprit? World Allergy Organization Journal, 10, 2-8. https://doi.org/10.1186/s40413-016-0138-8</Citation>
        </Reference>
        <Reference>
          <Citation>Martinez, F. D., &amp; Vercelli, D. (2013). Asthma. Lancet, 382, 1360-1372. https://doi.org/10.1016/S0140-6736(13)61536-6</Citation>
        </Reference>
        <Reference>
          <Citation>McGuire, J. J., Saifeddine, M., Triggle, C. R., Sun, K., &amp; Hollenberg, M. D. (2004). 2-Furoyl-LIGRLO-amide: A potent and selective proteinase-activated receptor 2 agonist. The Journal of Pharmacology and Experimental Therapeutics, 309, 1124-1131. https://doi.org/10.1124/jpet.103.064584</Citation>
        </Reference>
        <Reference>
          <Citation>McMahon, D. B., Workman, A. D., Kohanski, M. A., Carey, R. M., Freund, J. R., Hariri, B. M., Chen, B., Doghramji, L. J., Adappa, N. D., Palmer, J. N., Kennedy, D. W., &amp; Lee, R. J. (2018). Protease-activated receptor 2 activates airway apical membrane chloride permeability and increases ciliary beating. The FASEB Journal, 32, 155-167. https://doi.org/10.1096/fj.201700114RRR</Citation>
        </Reference>
        <Reference>
          <Citation>Moss, C. R. 2nd, Gilbert, C. A., Gabriel, S. A., &amp; Gu, Q. (2015). Protease-activated receptor-2 inhibits BK channel activity in bronchopulmonary sensory neurons. Neuroscience Letters, 589, 13-18. https://doi.org/10.1016/j.neulet.2015.01.020</Citation>
        </Reference>
        <Reference>
          <Citation>Nichols, H. L., Saffeddine, M., Theriot, B. S., Hegde, A., Polley, D., El-Mays, T., Vliagoftis, H., Hollenberg, M. D., Wilson, E. H., Walker, J. K., &amp; DeFea, K. A. (2012). β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proceedings of the National Academy of Sciences of the United States of America, 109, 16660-16665. https://doi.org/10.1073/pnas.1208881109</Citation>
        </Reference>
        <Reference>
          <Citation>Ock, M. S., Kim, B. J., Kim, S. M., &amp; Byun, K. H. (2005). Cloning and expression of trypsin-encoding cDNA from Blattella germanica and its possibility as an allergen. The Korean Journal of Parasitology, 43, 101-110. https://doi.org/10.3347/kjp.2005.43.3.101</Citation>
        </Reference>
        <Reference>
          <Citation>O'Grady, S. M., Patil, N., Melkamu, T., Maniak, P. J., Lancto, C., &amp; Kita, H. (2013). ATP release and Ca2+ signalling by human bronchial epithelial cells following Alternaria aeroallergen exposure. The Journal of Physiology, 591, 4595-4609. https://doi.org/10.1113/jphysiol.2013.254649</Citation>
        </Reference>
        <Reference>
          <Citation>Page, K., Ledford, J. R., Zhou, P., Dienger, K., &amp; Wills-Karp, M. (2010). Mucosal sensitization to German cockroach involves protease-activated receptor-2. Respiratory Research, 11, 62-71. https://doi.org/10.1186/1465-9921-11-62</Citation>
        </Reference>
        <Reference>
          <Citation>Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410</Citation>
        </Reference>
        <Reference>
          <Citation>Polley, D. J., Mihara, K., Ramachandran, R., Vliagoftis, H., Renaux, B., Saifeddine, M., Daines, M. O., Boitano, S., &amp; Hollenberg, M. D. (2017). Cockroach allergen serine proteinases: Isolation, sequencing and signalling via proteinase-activated receptor-2. Clinical and Experimental Allergy, 47, 946-960. https://doi.org/10.1111/cea.12921</Citation>
        </Reference>
        <Reference>
          <Citation>Pulimood, T. B., Corden, J. M., Bryden, C., Sharples, L., &amp; Nasser, S. M. (2007). Epidemic asthma and the role of the fungal mold Alternaria alternata. The Journal of Allergy and Clinical Immunology, 120, 610-617. https://doi.org/10.1016/j.jaci.2007.04.045</Citation>
        </Reference>
        <Reference>
          <Citation>Ramachandran, R., Noorbakhsh, F., Defea, K., &amp; Hollenberg, M. D. (2012). Targeting proteinase-activated receptors: Therapeutic potential and challenges. Nature Reviews. Drug Discovery, 11, 69-86. https://doi.org/10.1038/nrd3615</Citation>
        </Reference>
        <Reference>
          <Citation>Rayees, S., Joshi, J. C., Tauseef, M., Anwar, M., Baweja, S., Rochford, I., Joshi, B., Hollenberg, M. D., Reddy, S. P., &amp; Mehta, D. (2019). PAR2-mediated cAMP generation suppresses TRPV4-dependent Ca2+ signaling in alveolar macrophages to resolve TLR4-induced inflammation. Cell Reports, 27, 793-805.e794. https://doi.org/10.1016/j.celrep.2019.03.053</Citation>
        </Reference>
        <Reference>
          <Citation>Sevigny, L. M., Zhang, P., Bohm, A., Lazarides, K., Perides, G., Covic, L., &amp; Kuliopulos, A. (2011). Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proceedings of the National Academy of Sciences, 108, 8491-8496. https://doi.org/10.1073/pnas.1017091108</Citation>
        </Reference>
        <Reference>
          <Citation>Shrestha Palikhe, N., Nahirney, D., Laratta, C., Gandhi, V. D., Vethanayagam, D., Bhutani, M., Mayers, I., Cameron, L., &amp; Vliagoftis, H. (2015). Increased protease-activated receptor-2 (PAR-2) expression on CD14++CD16+ peripheral blood monocytes of patients with severe asthma. PLoS ONE, 10, e0144500. https://doi.org/10.1371/journal.pone.0144500</Citation>
        </Reference>
        <Reference>
          <Citation>Snelgrove, R. J., Gregory, L. G., Peiró, T., Akthar, S., Campbell, G. A., Walker, S. A., &amp; Lloyd, C. M. (2014). Alternaria-derived serine protease activity drives IL-33-mediated asthma exacerbations. The Journal of Allergy and Clinical Immunology, 134, 583-592.e586. https://doi.org/10.1016/j.jaci.2014.02.002</Citation>
        </Reference>
        <Reference>
          <Citation>Suen, J. Y., Barry, G. D., Lohman, R. J., Halili, M. A., Cotterell, A. J., Le, G. T., &amp; Fairlie, D. P. (2012). Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). British Journal of Pharmacology, 165, 1413-1423. https://doi.org/10.1111/j.1476-5381.2011.01610.x</Citation>
        </Reference>
        <Reference>
          <Citation>To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., &amp; Boulet, L. P. (2012). Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health, 12, 204-211. https://doi.org/10.1186/1471-2458-12-204</Citation>
        </Reference>
        <Reference>
          <Citation>Yau, M. K., Lim, J., Liu, L., &amp; Fairlie, D. P. (2016). Protease activated receptor 2 (PAR2) modulators: A patent review (2010-2015). Expert Opinion on Therapeutic Patents, 26, 471-483. https://doi.org/10.1517/13543776.2016.1154540</Citation>
        </Reference>
        <Reference>
          <Citation>Yee, M. C., Nichols, H. L., Polley, D., Saifeddine, M., Pal, K., Lee, K., Wilson, E. H., Daines, M. O., Hollenberg, M. D., Boitano, S., &amp; DeFea, K. A. (2018). Protease-activated receptor-2 signaling through β-arrestin-2 mediates Alternaria alkaline serine protease-induced airway inflammation. American Journal of Physiology. Lung Cellular and Molecular Physiology, 315, L1042-L1057. https://doi.org/10.1152/ajplung.00196.2018</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou, Y., Zhang, Y., Guo, Y., Zhang, Y., Xu, M., &amp; He, B. (2014). β2-Adrenoceptor involved in smoking-induced airway mucus hypersecretion through β-arrestin-dependent signaling. PLoS ONE, 9, e97788. https://doi.org/10.1371/journal.pone.0097788</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
